Go to article
Posted by Peter on 2-3 2:36 pm
Tags: axicabtagene ciloleucel, B-cell acute lymphoblastic leukemia, big pharma, biotechs, CAR-T, chimeric antigen receptor T-cell, cost issue, current cancer treatments, diffuse large B-cell lymphoma, DLBCL, expensive to produce, Food and Drug Administration, higher efficacy, investors, justify a higher price, Kite Pharma, new way to treat cancer, Novartis, offering money-back guarantees, personalized treatments, PMBCL, premium price, primary mediastinal B-cell lymphoma, pushback from insurers, refractory, relapsed, TFL, therapies, tisagenlecleucel-T, transformed follicular lymphoma, treat cancer
Categories:
General
Innovation
Market
Technology
The Industry
